Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2023-05-23 00:00:00 ET · period of report 2023-05-19 · accession 0001610717-23-000061 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-23 | 2023-05-19 | CTMX | McCarthy Sean A. | CEO, Dir | M - OptEx | $1.57 | +16.5K | 405.4K | +4% | +$26.0K |
| D | 2023-05-23 | 2023-05-19 | CTMX | McCarthy Sean A. | CEO, Dir | M - OptEx | $0.00 | -16.5K | 119.5K | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-19 | M | A | 16,535 | $1.57 | 405,356 | D | — | — | (F1) Includes 161,250 restricted stock units. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-05-19 | M | D | 16,535 | $0.00 | 119,536 | D | $1.57 · — to 2025-02-08 | 16,535 Common Stock | (F3) This option is fully vested and exercisable. |